pharmaceuticals

Another Cancer-Drug Failure Highlights Difficulties Facing Pharmas

Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as they scramble to bolster their pipelines ahead of the patent cliff, when they will be forced to compete with cheaper generics.

As Diabetes Explodes, Big Pharma Is Gearing Up

Diabetes is a growing global scourge, but for Big Pharma it's more of a lifesaver. As the number of people with diabetes and prediabetes explodes, drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes could be a $55 billion market by 2019.

Government Recoups $4 Billion from Health Care Fraud Cases

The government recouped a staggering $4 billion in fiscal 2010 that was stolen from federal health care programs, the departments of Justice and Health and Human Services announced Monday -- the highest annual amount ever. More than half of the fraud money recovered came from drug companies.

Glaxo Faces First of Many Possible Avandia Trials

Did GlaxoSmithKline's blockbuster diabetes drug Avandia cause fatal heart attacks? The first federal trial of an Avandia lawsuit began this morning in Philidelphia. As many as 50,000 more lurk in the wings.

What Pfizer Sees in Lpath's Innovative Blindness Drugs

Lpath focuses on developing therapeutics that target bioactive lipids for treating a range of human diseases, including cancer and diseases that cause blindness. Its promising drugs have attracted attention -- and lots of money -- from Pfizer. More of both could be coming.

A Depressing Outlook for Big Pharma's Next Few Years

After several years of robust expansion, the leading branded pharma companies will see growth slow to just 1.3% from now to 2015, independent market analyst company Datamonitor said in a new report. The primary culprit: expiring patents and an onslaught of generic competition.

Drug Shortages: A Deadly Problem With No Cure in Sight

If gasoline or jobs or milk were in short supply, we'd all know about it. But unknown to most Americans, the country is now in the grips of a life-threatening drug shortage. Medical professionals are quite aware of it, however, and they're deeply concerned.

Which Sector Lost the Most Jobs in 2010? Pharma

If you don't count the U.S. government and nonprofits, the pharmaceutical industry had the most job cuts last year. Mergers, acquisitions and major restructurings made pharma a much smaller and leaner sector -- will those changes now play in its favor?

Genzyme Talks Up Possible Sales of Its New MS Drug

Biotechnology company Genzyme is holding an analyst and investor meeting Monday focused on the commercial potential of its multiple sclerosis drug Campath as it tries to convince Sanofi-Aventis that it's worth more than the Paris-based pharmaceutical giant has been offering.

Pharmaceuticals Reveal Latest on Blood Disease Drugs

At the 52nd annual meeting of the American Society of Hematology, which wraps up Tuesday, Novartis, Celgene and Seattle Genetics revealed the latest news from their studies on blood diseases and cancers. But despite some positive results, all three had down days in the stock market.

Tiny Spectrum Pharmaceuticals Is Getting Plenty of Attention

What's Spectrum's particular allure? Beyond being the subject of takeover rumor, it has two oncology drugs approved by the Food and Drug Administration that are already on the market, plus two other promising drugs that are in late-stage clinical trials.

Can GE and J&J Help Detect Alzheimer's Earlier?

Medical imaging and diagnostics powerhouse GE Healthcare teams up with pharmaceutical giant Johnson & Johnson to research methods of detecting Alzheimer's in patients -- even before they begin to exhibit symptoms of the devastating disease.

The New-Drug Pipeline: U.S. Biotechs Lead the Way

The U.S. leads the world in creating new drugs, and big pharmaceutical companies companies play an important role in the process. But according to a new study, a unique system of collaboration between universities and small biotech firms is the key to the system.

Pharma News Briefs: Human Genome, Merck, Novartis

Here's a roundup of some of Wednesday's major pharmaceutical news: An FDA panel gave Human Genome Sciences a boost with a thumbs-up for its lupus drug, Benlysta; Merck's experimental heart drug appears to work well without side effects; and Novartis announced its plans for long-term growth.

How to Approve 'Biosimilar' Drugs? The FDA Has to Figure That Out

Unlike generics, which are the exact chemical copies of a brand-name drug, biosimilars have large and often complex proteins that are made in living cells, and tiny differences can play havoc with the product. It may take years for the FDA to create an approval process.

Growing Interest
in Achillion's Hepatitis Drugs

At a liver disease conference in Boston, one of the highlights is expected to be reports from Achillion about its novel hepatitis C treatments, especially ACH-1625. The buzz is growing stronger that the little biotech is attracting the attention of some players in Big Pharma.

Russia Investigates Alleged Spam Kingpin

Russia%u2019s police may have cut down the amount of spam in your inbox by opening an investigation of an alleged spam kingpin. Russian officials began the investigation of Igor A. Gusev Tuesday, The New York Times reported. Officials said Gusev likely fled the country.

DuPont Earnings Drop, but Raises Outlook

DuPont (DD) reported third-quarter earnings of 40 cents per share, down from 45 cents per share a year earlier. Sales grew 17% from a year earlier to $7 billion, the company said in a statement. Sales grew 22% in emerging markets.

A New Antidepressant Maker Has Lots of Folks Excited

Tiny, little-known biotech Clinical Data has developed a potential blockbuster drug called Vilazodone. If OK'd, it would be the first new depression treatment in 15 years. Its potential is so huge that several Big Pharmas are said to looking to buy the startup.